References: Vancomycin dosing, monitoring and dosage adjustment in adults undergoing dialysis

  • Allawati H, Dallas L, Nair S, Palmer J, Thaikandy S, Hutchison C. A Pharmacokinetic Study Comparing the Clearance of Vancomycin during Haemodialysis Using Medium Cut-Off Membrane (Theranova) and High-Flux Membranes (Revaclear). Toxins (Basel) 2020;12(5). https://www.ncbi.nlm.nih.gov/pubmed/32408589
  • Fu CF, Huang JD, Wang JT, Lin SW, Wu CC. The ratio of pre-dialysis vancomycin trough serum concentration to minimum inhibitory concentration is associated with treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia. PLoS One 2018;13(3):e0193585. https://www.ncbi.nlm.nih.gov/pubmed/29505620
  • Hartinger JM, Sima M, Hronova K, Halouzkova BA, Szonowska B, Polakovic V, et al. Vancomycin pharmacokinetics in patients treated with intermittent haemodialysis based on therapeutic drug monitoring. J Chemother 2022;34(3):149-56. https://www.ncbi.nlm.nih.gov/pubmed/34551680
  • Hui K, Patel K, Nalder M, Nelson C, Buising K, Pedagogos E, et al. Optimizing vancomycin dosage regimens in relation to high-flux haemodialysis. J Antimicrob Chemother 2019;74(1):130-4. https://www.ncbi.nlm.nih.gov/pubmed/30215721
  • Launay-Vacher V, Izzedine H, Mercadal L, Deray G. Clinical review: use of vancomycin in haemodialysis patients. Crit Care 2002;6(4):313-6. https://www.ncbi.nlm.nih.gov/pubmed/12225605
  • Lewis SJ, Mueller BA. Evaluation and Development of Vancomycin Dosing Schemes to Meet New AUC/MIC Targets in Intermittent Hemodialysis Using Monte Carlo Simulation Techniques. J Clin Pharmacol 2021;61(2):211-23. https://www.ncbi.nlm.nih.gov/pubmed/32851685
  • Ogawa A, Hira D, Tsujimoto M, Nishiguchi K, Endo M, Ono T, et al. Optimal Sampling Strategy and Threshold of Serum Vancomycin Concentration in Elderly Japanese Patients Undergoing High-Flux Hemodialysis. Ther Drug Monit 2022;44(3):396-403. https://www.ncbi.nlm.nih.gov/pubmed/34407000
  • Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020;77(11):835-64. https://www.ncbi.nlm.nih.gov/pubmed/32191793
  • Zelenitsky SA, Ariano RE. An updated vancomycin dosing protocol for initiating therapy in patients undergoing intermittent high-flux hemodialysis. Am J Health Syst Pharm 2022;79(12):1006-10. https://www.ncbi.nlm.nih.gov/pubmed/35234825